The latest evidence in the Management of Neuromuscular Blockade

Report this content

News: Uppsala, June 3, 2020. Senzime AB (publ) today announces that they are the proud sponsor
of a free webinar on the management of neuromuscular blockade.

This educational webinar is designed to provide insight into the latest evidence of post-operative residual neuromuscular blockade, antagonist strategies to reduce PORC and a
technology review of current monitoring technologies.

Meet the experts and join us on Wednesday June 17th!  Space is limited, book your place here:


REGISTER LINK: Early session

REGISTER LINK: Late session



Senzime’s TetraGraph neuromuscular monitor is a unique digital system designed to address
the needs of perioperative monitoring of physiologic data in surgical patients receiving general anesthesia and muscle relaxation using neuromuscular blocking drugs (NMBAs). The TetraGraph stimulates a peripheral nerve and measures, analyzes and displays in real-time the muscle
function in surgical patients who receive NMBAs as part of their general anesthetic.

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                                                                          

Tel: +46 (0)70-813 34 17, email:


About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq
First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, is Certified Adviser for Senzime.




Documents & Links